Interestingly, this genome-wide study, as well as previous studies of early-onset pancreatic phenotypes that identified SLC26A9 as a CF modifier [12–14], highlight that SLC26A9 and CFTR may not require interaction in the pancreas in the same way apparent for the lung phenotype. Here, SLC26A9 is linked to cystic fibrosis.